Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced progress in its strategic acquisition initiatives aimed at complementing its biotechnology and AI businesses. The planned acquisitions, including a contract research organization (CRO), could potentially produce approximately $100 million in combined annual revenue, supporting the company’s goal to…